FXR also upregulates FGF19 (fibroblast growth factor 19) which is anti-cholestatic and anti-fibrotic factor in the liver and was proposed for the treatment of NASH. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatohepatitis.